Non-continuous mobile electrocardiogram monitoring for post-transcatheter aortic valve replacement delayed conduction disorders put to the test.
Delayed conduction disturbances
Handheld electrocardiogram
Mobile health
Transcatheter aortic valve replacement
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
30 03 2023
30 03 2023
Historique:
received:
11
08
2022
accepted:
28
12
2022
medline:
3
4
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Permanent pacemaker implantation (PPM-I) remains nowadays the most important drawback of transcatheter aortic valve replacement (TAVR) procedure and the optimal strategy of delayed conduction disturbances (CDs) in these patients is unclear. The study aimed to validate an ambulatory electrocardiogram (ECG) monitoring through a 30 s spot ambulatory digital mobile ECG (AeECG), by using KardiaMobile-6L device in a 30-day period after TAVR procedure. Between March 2021 and February 2022, we consecutively enrolled all patients undergoing TAVR procedure, except pacemaker (PM) carriers. At discharge, all patients were provided of a KardiaMobile-6L device and a spot digital ECG (eECG) recording 1 month schedule. Clinical and follow-up data were collected, and eECG schedule compliance and recording quality were explored. Among 151 patients without pre-existing PM, 23 were excluded for pre-discharge PPM-I, 18 failed the KardiaMobile-6L training phase, and 10 refused the device. Delayed CDs with a Class I/IIa indication for PPM-I occurred in eight patients (median 6 days). Delayed PPM-I vs. non-delayed PPM-I patients were more likely to have longer PR and QRS intervals at discharge. PR interval at discharge was the only independent predictor for delayed PPM-I at multivariate analysis. The overall eECG schedule compliance was 96.5%. None clinical adverse events CDs related were documented using this new AeECG monitoring modality. A strategy of 30 s spot AeECG is safe and efficacious in delayed CDs monitoring after TAVR procedure with a very high eECG schedule level of compliance.
Identifiants
pubmed: 36691737
pii: 7000049
doi: 10.1093/europace/euac285
pmc: PMC10062351
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1116-1125Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230
pubmed: 27956264
Circulation. 2017 Sep 12;136(11):1049-1069
pubmed: 28893961
Europace. 2021 Dec 7;23(12):1998-2009
pubmed: 34379760
Heart Vessels. 2019 Feb;34(2):360-367
pubmed: 30083944
CJC Open. 2020 Apr 25;2(5):416-419
pubmed: 32995727
Eur Heart J. 2021 Sep 14;42(35):3427-3520
pubmed: 34455430
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1269-1276
pubmed: 27339844
Europace. 2022 Oct 13;24(9):1475-1483
pubmed: 35699482
Cardiovasc Revasc Med. 2020 Apr;21(4):475-478
pubmed: 31431323
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
J Am Coll Cardiol. 2019 May 28;73(20):2538-2547
pubmed: 31118148
Int J Cardiol. 2017 May 1;234:16-21
pubmed: 28258844
JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt A):1148-1150
pubmed: 28412418
Heart Rhythm. 2018 Oct;15(10):1561-1565
pubmed: 30143448
J Am Coll Cardiol. 2021 Mar 16;77(10):1344-1356
pubmed: 33706878
Ann Noninvasive Electrocardiol. 2021 Nov;26(6):e12872
pubmed: 34288227
JACC Cardiovasc Interv. 2021 Jan 25;14(2):115-134
pubmed: 33478630
JACC Cardiovasc Interv. 2018 Aug 13;11(15):1495-1505
pubmed: 30031719
Circ Cardiovasc Interv. 2016 May;9(5):e003635
pubmed: 27169577
JACC Cardiovasc Interv. 2021 Oct 11;14(19):2173-2181
pubmed: 34620397
Eur Heart J. 2018 Jun 1;39(21):2003-2013
pubmed: 29420704
JACC Cardiovasc Interv. 2018 Aug 13;11(15):1519-1526
pubmed: 30093056
JACC Cardiovasc Interv. 2016 Nov 14;9(21):2189-2199
pubmed: 27832844